Aim and learning objectives :

1. Introducing sodium-glucose co-transporter 2 (SGLT2) inhibitors: indications, mechanism of action, advantages and limitations

2. Revising the pathophysiology of diabetic ketoacidosis (DKA) and the association of SGLT2 inhibitors with euglycemic DKA 3. Sharing a case study to elucidate the precautions of SGLT2 inhibitors and appropriate monitoring strategies for euglycemic DKA

Expected outcomes :

1. To raise awareness of the necessity to discontinue SGLT2 inhibitors at least 3 days before surgery or other invasive procedure requiring prolonged fasting

2. To highlight the importance of monitoring for DKA following surgery or procedure, and after resuming with SGLT2 inhibitors